Mitral Stenosis Follow-up

  • Author: Claudia Dima, MD; Chief Editor: Richard A Lange, MD   more...
 
Updated: Nov 1, 2010
 

Further Outpatient Care

  • Serial follow-up testing of a patient with mitral stenosis should be based on whether the results of a test will dictate either a change in therapy or a recommendation for a procedure.
  • All patients should be informed that any change in symptoms warrants re-evaluation.
  • In the asymptomatic patient, yearly re-evaluation is recommended; history, physical examination, chest radiograph, and echocardiogram (ECG) should be obtained.
  • An echocardiogram is not recommended yearly unless there is a change in clinical status or the patient has severe mitral stenosis.
  • Ambulatory ECG monitoring (Holter or event recorder) to detect paroxysmal atrial fibrillation is indicated in patients with palpitations.
Next

Deterrence/Prevention

  • Primary prevention of acute rheumatic fever[3] (see Table 3 below).
  • Secondary prevention of rheumatic fever (see Medical Care).
  • Infective endocarditis prophylaxis (see Medical Care).

Table 3. Primary Prevention of Rheumatic Fever (Treatment of Streptococcal Tonsillopharyngitis*) (Open Table in a new window)

AgentDoseModeDurationRating †
Penicillins
Penicillin V (phenoxymethyl penicillin)Children 27 kg (60 lb): 250 mg bid or tid



Patients >27 kg: 500 mg bid or tid



Oral10 dIB
Amoxicillin50 mg/kg qd (maximum 1 g)Oral10 dIB
Benzathine penicillin GChildren 27 kg (60 lb): 600,000 U



Patients >27 kg: 1,200,000 U



IntramuscularOnceIB
For individuals allergic to penicillin
Narrow-spectrum cephalosporin (cephalexin, cefadroxil)VariableOral10 dIB
Clindamycin20 mg/kg/d divided in 3 doses (maximum 1.8 g/d)Oral10 dIIaB
Azithromycin12 mg/kg qd (maximum 500 mg)Oral5 dIIaB
Clarithromycin15 mg/kg/d divided bid (maximum 250 mg bid)Oral10 dIIaB
*Sulfonamides, trimethoprim, tetracyclines, and fluoroquinolones are not acceptable.



† Rating indicates classification of recommendation and level of evidence (eg, IB indicates Class I, level of Evidence B)



Previous
Next

Complications

  • Atrial fibrillation
  • Systemic embolism due to left atrial thrombus formation mostly secondary to atrial fibrillation: 20% of patients with mitral stenosis and systemic embolism are in sinus rhythm.
  • Infective endocarditis: Estimated risk of endocarditis in a patient with mitral stenosis is 0.17 per 1000 patient-years.
  • Pulmonary hypertension
  • Pulmonary edema
  • Complications of balloon valvotomy
  • Complications of mitral valve replacement
Previous
Next

Prognosis

  • In the presurgical era, symptomatic patients with mitral stenosis had a poor outlook with 5-year survival rates of 62% among patients with mitral stenosis in NYHA Class III and only 15% among those in Class IV.
  • Data from unoperated patients in the surgical era still report a 5-year survival rate of only 44% in patients with symptomatic mitral stenosis who refused valvotomy.[8]
  • Overall clinical outcomes are greatly improved in patients who undergo surgical or percutaneous relief of valve obstruction based on current guidelines. However, longevity is still shortened compared with expected for age, largely because of complications of the disease process.
Previous
Next

Patient Education

All patients should be informed about the following:

  • Signs and symptoms of severe mitral stenosis (Patients should be advised to present for re-evaluation.)
  • Secondary prevention of rheumatic fever
  • Infective endocarditis prophylaxis
  • Need for chronic evaluation if atrial fibrillation is present
  • Evaluation of new-onset palpitations for possible atrial fibrillation if not previously diagnosed
Previous
 
Contributor Information and Disclosures
Author

Claudia Dima, MD  Cardiovascular Fellow, Department of Cardiology, Banner Good Samaritan Medical Center

Disclosure: Nothing to disclose.

Coauthor(s)

Kenneth B Desser, MD  Clinical Professor, Director of Cardiology Fellowship, Banner Good Samaritan Medical Center, Phoenix, Arizona

Disclosure: Nothing to disclose.

Specialty Editor Board

L Michael Prisant, MD, FACC, FAHA  Cardiologist, Emeritus Professor of Medicine, Medical College of Georgia

L Michael Prisant, MD, FACC, FAHA is a member of the following medical societies: American College of Cardiology, American College of Chest Physicians, American College of Clinical Pharmacology, American College of Forensic Examiners, American College of Physicians, American Heart Association, and American Medical Association

Disclosure: Boehringer-Ingelheim Honoraria Speaking and teaching

Francisco Talavera, PharmD, PhD  Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Steven J Compton, MD, FACC, FACP  Director of Cardiac Electrophysiology, Alaska Heart Institute, Providence and Alaska Regional Hospitals

Steven J Compton, MD, FACC, FACP is a member of the following medical societies: Alaska State Medical Association, American College of Cardiology, American College of Physicians, American Heart Association, American Medical Association, and Heart Rhythm Society

Disclosure: Nothing to disclose.

Amer Suleman, MD  Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital

Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions

Disclosure: Nothing to disclose.

Chief Editor

Richard A Lange, MD  Professor and Executive Vice Chairman, Department of Medicine, Director, Office of Educational Programs, University of Texas Health Science Center at San Antonio

Richard A Lange, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Heart Association, and Association of Subspecialty Professors

Disclosure: Nothing to disclose.

References

  1. Marcus RH, Sareli P, Pocock WA, et al. The spectrum of severe rheumatic mitral valve disease in a developing country. Correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae. Ann Intern Med. Feb 1 1994;120(3):177-83. [Medline].

  2. Bruce CJ, Nishimura RA. Newer advances in the diagnosis and treatment of mitral stenosis. Curr Probl Cardiol. Mar 1998;23(3):125-92. [Medline].

  3. [Guideline] Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. Mar 24 2009;119(11):1541-51. [Medline].

  4. Antonini-Canterin F, Moura LM, Enache R, Leiballi E, Pavan D, Piazza R. Effect of hydroxymethylglutaryl coenzyme-a reductase inhibitors on the long-term progression of rheumatic mitral valve disease. Circulation. May 18 2010;121(19):2130-6. [Medline].

  5. [Guideline] Nishimura RA, Carabello BA, Faxon DP, Freed MD, Lytle BW, O'Gara PT. ACC/AHA 2008 Guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. Aug 19 2008;52(8):676-85. [Medline].

  6. Feldman T. Rheumatic Mitral Stenosis. Curr Treat Options Cardiovasc Med. Apr 2000;2(2):93-104. [Medline].

  7. Rahimtoola SH. Choice of Prosthetic Heart Valve in Adults An Update. J Am Coll Cardiol. Jun 1 2010;55(22):2413-2426. [Medline].

  8. Horstkotte D, Niehues R, Strauer BE. Pathomorphological aspects, aetiology and natural history of acquired mitral valve stenosis. Eur Heart J. Jul 1991;12 Suppl B:55-60. [Medline].

  9. [Guideline] Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. Sep 23 2008;52(13):e1-142. [Medline].

  10. Bonow RO, Otto CM. Valvular heart disease. In: Libby P, Bonow RO, Mann DL, Zipes DP. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 2. 8th ed. Philadelphia, PA: WB Saunders; 2008:1646-1657.

  11. Carabello BA. Modern management of mitral stenosis. Circulation. Jul 19 2005;112(3):432-7. [Medline].

 
Previous
Next
 
M-mode across the mitral valve showing a flat E-F slope resulting from elevated left atrial pressure throughout diastole due to a significant gradient across the mitral valve. Increased thickness and calcification of anterior leaflet of the mitral valve and decreased opening of the anterior and posterior leaflets in diastole are also shown.
Parasternal long-axis view demonstrating calcification and doming in diastole of the anterior valve leaflet and mild restriction in the opening of posterior mitral valve leaflet.
Apical 4-chamber view demonstrating restricted opening of the anterior and posterior mitral valve leaflet with diastolic doming of anterior leaflet with left atrial enlargement.
Transesophageal echocardiogram with continuous wave Doppler interrogation across the mitral valve demonstrating an increased mean gradient of 16 mm Hg consistent with severe mitral stenosis.
Apical 4-chamber view with color Doppler demonstrating aliasing in the atrial side of the mitral valve consistent with increased gradient across the valve. This figure also shows mitral regurgitation and left atrial enlargement.
Magnified view of the mitral valve in apical 4-chamber view revealing restricted opening of both leaflets.
Transesophageal echocardiogram in an apical 3-chamber view showing calcification and doming of the anterior mitral leaflet and restricted opening of both leaflets.
Transesophageal echocardiogram in an apical 3-chamber view with color Doppler interrogation of the mitral valve revealing aliasing, which is consistent with increased gradient across the mitral valve secondary to stenosis. Also shown in this image, a posteriorly directed jet of severe mitral regurgitation.
Table 1. Duration of Secondary Rheumatic Fever Prophylaxis
CategoryDuration After Last AttackRating*
Rheumatic fever with carditis and residual heart disease (persistent valvular disease† )10 y or until age 40 y (whichever is longer); sometimes lifelong prophylaxisIC
Rheumatic fever with carditis but no residual heart disease (no valvular disease† )10 y or until age 21 y (whichever is longer)IC
Rheumatic fever without carditis5 y or until age 21 y (whichever is longer)IC
*Rating indicates classification of recommendation and level of evidence (eg, IC indicates Class I, level of Evidence C).



†Clinical or echocardiographic evidence.



Table 2. Secondary Prevention of Rheumatic Fever (Prevention of Recurrent Attacks)
AgentDoseModeRating*
Benzathine penicillin GChildren 27 kg (60 lb): 600,000 U



Patients >27 kg: 1,200,000 every 4 wk†



IntramuscularIA
Penicillin V250 mg bidOralIB
SulfadiazineChildren 27 kg: 0.5 g qd



Patients >27 kg: 1 g qd



OralIB
Macrolide or azalide (for individuals allergic to penicillin and sulfadiazine)VariableOralIC
*Rating indicates classification of recommendation and level of evidence (eg, IA indicates Class I, level of Evidence A).



†In high-risk situations, administration every 3 weeks is justified and recommended.



Table 3. Primary Prevention of Rheumatic Fever (Treatment of Streptococcal Tonsillopharyngitis*)
AgentDoseModeDurationRating †
Penicillins
Penicillin V (phenoxymethyl penicillin)Children 27 kg (60 lb): 250 mg bid or tid



Patients >27 kg: 500 mg bid or tid



Oral10 dIB
Amoxicillin50 mg/kg qd (maximum 1 g)Oral10 dIB
Benzathine penicillin GChildren 27 kg (60 lb): 600,000 U



Patients >27 kg: 1,200,000 U



IntramuscularOnceIB
For individuals allergic to penicillin
Narrow-spectrum cephalosporin (cephalexin, cefadroxil)VariableOral10 dIB
Clindamycin20 mg/kg/d divided in 3 doses (maximum 1.8 g/d)Oral10 dIIaB
Azithromycin12 mg/kg qd (maximum 500 mg)Oral5 dIIaB
Clarithromycin15 mg/kg/d divided bid (maximum 250 mg bid)Oral10 dIIaB
*Sulfonamides, trimethoprim, tetracyclines, and fluoroquinolones are not acceptable.



† Rating indicates classification of recommendation and level of evidence (eg, IB indicates Class I, level of Evidence B)



Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.